AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28185643 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral triiodothyronine (T3; 1 μg/kg per body weight/dose) administered every 6 hours for 60 hours after induction of anesthesia
Number of subjects: 205
Study 28185643 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral triiodothyronine (T3)
Number of subjects: 205
Study 28185643 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saccharum lactis)
Number of subjects: 205
Study 25591992 — intervention group
Group type: EXPERIMENTAL
Intervention: Avanafil 100 mg
Number of subjects: 440
Study 25591992 — intervention group
Group type: EXPERIMENTAL
Intervention: Avanafil 200 mg
Number of subjects: 440
Study 25591992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study 24378658 — intervention group
Group type: EXPERIMENTAL
Intervention: E-R (Endurance before Resistance)
Number of subjects: 23
Study 24378658 — intervention group
Group type: EXPERIMENTAL
Intervention: R-E (Resistance before Endurance)
Number of subjects: 23
Study 24378658 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 23
Study 22775479 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Xilei San (0.1 g/dose per day)
Number of subjects: 30
Study 22775479 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Xilei San
Number of subjects: 30
Study 22775479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19541567 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest vibration nursing intervention (mechanical chest wall vibration pad for 60 minutes, 6 times a day for 72 hours)
Number of subjects: 95
Study 19541567 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest vibration nursing intervention
Number of subjects: 95
Study 19541567 — intervention group
Group type: COMPARATOR
Intervention: Routine positioning care (control group, change in body position every 2 hours)
Number of subjects: 95
Study 17700222 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg/day)
Number of subjects: 43
Study 17700222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 15831796 — intervention group
Group type: EXPERIMENTAL
Intervention: High-glycemic index (HGI) carbohydrate breakfast (2.5g CHO/kg body mass)
Number of subjects: 7
Study 15831796 — intervention group
Group type: COMPARATOR
Intervention: Low-glycemic index (LGI) carbohydrate breakfast (2.5g CHO/kg body mass)
Number of subjects: 7
Study 15831796 — intervention group
Group type: EXPERIMENTAL
Intervention: High-glycemic index (HGI) carbohydrate breakfast
Number of subjects: 7
Study 15831796 — intervention group
Group type: COMPARATOR
Intervention: Low-glycemic index (LGI) carbohydrate breakfast
Number of subjects: 7
Study 11953077 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin patch
Number of subjects: 60
Study 11953077 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate and salbutamol sulfate
Number of subjects: 60
Study 9798803 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg o.d.
Number of subjects: 248
Study 9798803 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg o.d.
Number of subjects: 248
Study 7706102 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized intermittent mandatory ventilation (SIMV) with 10 cm H2O pressure support
Number of subjects: 10
Study 7706102 — intervention group
Group type: COMPARATOR
Intervention: Assist-control
Number of subjects: 10
Study 7706102 — intervention group
Group type: COMPARATOR
Intervention: Synchronized intermittent mandatory ventilation (SIMV)
Number of subjects: 10
Study 7706102 — intervention group
Group type: COMPARATOR
Intervention: All three modes of mechanical ventilation
Number of subjects: 10
Study 2132303 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchiectomy
Number of subjects: 200
Study 2132303 — intervention group
Group type: COMPARATOR
Intervention: Polyoestradiol phosphate (PEP) 160 mg/month i.m.
Number of subjects: 200
Study 453276 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic fetal monitoring alone
Number of subjects: 690
Study 453276 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic monitoring with the option to scalp sample
Number of subjects: 690
Study 453276 — intervention group
Group type: COMPARATOR
Intervention: Auscultation
Number of subjects: 690
Study 453276 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (auscultation, electronic fetal monitoring alone, electronic monitoring with scalp sample)
Number of subjects: 690
Study 31915308 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (dose not specified) over 28 days
Number of subjects: 64
Study 31915308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 30219327 — intervention group
Group type: EXPERIMENTAL
Intervention: CTO PCI
Number of subjects: 205
Study 30219327 — intervention group
Group type: COMPARATOR
Intervention: No CTO PCI
Number of subjects: 205
Study 25424132 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised implementation of an oral healthcare protocol and education
Number of subjects: 120
Study 25424132 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study 23978872 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 mg/day UDCA
Number of subjects: 20
Study 23978872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 22264193 — intervention group
Group type: EXPERIMENTAL
Intervention: Playing a first-person shooter video game for a cumulative total of 10 hours
Number of subjects: 25
Study 19710354 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Care (GC)
Number of subjects: 196
Study 18346976 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) treatment
Number of subjects: 12
Study 18346976 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone and NSAIDs (Control)
Number of subjects: 12
Study 16163627 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir 125 mg twice daily for 5 days
Number of subjects: 308
Study 16163627 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir 250 mg twice daily for 5 days
Number of subjects: 308
Study 16163627 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir 500 mg twice daily for 5 days
Number of subjects: 308
Study 16163627 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir (all doses)
Number of subjects: 308
Study 16163627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study 12188088 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact bovine colostrum protein powder (60 g x day(‐1))
Number of subjects: 30
Study 12188088 — intervention group
Group type: COMPARATOR
Intervention: Concentrated whey protein powder placebo
Number of subjects: 30
Study 10815307 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium alginate
Number of subjects: 30
Study 10815307 — intervention group
Group type: COMPARATOR
Intervention: Silicone-coated polyamide net dressing
Number of subjects: 30
Study 10815307 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 8979563 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbitone (PB)
Number of subjects: 151
Study 8979563 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (PHT)
Number of subjects: 151
Study 8979563 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Valproate (SVP)
Number of subjects: 151
Study 8979563 — intervention group
Group type: COMPARATOR
Intervention: All three drugs (PB, PHT, SVP)
Number of subjects: 151
Study 2061417 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% metronidazole
Number of subjects: 19
Study 2061417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 6150121 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal, 50 g, given 5 min after 400 mg cimetidine + 10 mg pindolol
Number of subjects: 7
Study 6150121 — intervention group
Group type: EXPERIMENTAL
Intervention: Syrup of ipecac
Number of subjects: 7
Study 30590425 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 21104
Study 30590425 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose edoxaban
Number of subjects: 21104
Study 30590425 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 21104
Study 29462506 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPT (extended-release tacrolimus tablets)
Number of subjects: 0
Study 27244765 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin 0.1 mg (Group A)
Number of subjects: 91
Study 27244765 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin 50 µg (Group B)
Number of subjects: 91
Study 27244765 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin 25 µg (Group C)
Number of subjects: 91
Study 27244765 — intervention group
Group type: COMPARATOR
Intervention: Group A
Number of subjects: 91
Study 27244765 — intervention group
Group type: COMPARATOR
Intervention: Group B
Number of subjects: 91
Study 27244765 — intervention group
Group type: COMPARATOR
Intervention: Group C
Number of subjects: 91
Study 25755182 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh intermuscular fat (per SD increment) in men
Number of subjects: 5187
Study 25755182 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral fat (per SD increment) in women
Number of subjects: 5187
Study 25755182 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal subcutaneous fat (per SD increment) in women
Number of subjects: 5187
Study 21929830 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-session CBT-based panic management intervention (PMI)
Number of subjects: 58
Study 21929830 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-session CBT intervention
Number of subjects: 58
Study 21929830 — intervention group
Group type: COMPARATOR
Intervention: Usual care control condition
Number of subjects: 58
Study 20337206 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (5 mg daily from day 3-7 of menstrual cycle)
Number of subjects: 107
Study 20337206 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (100 mg daily from day 3-7 of menstrual cycle)
Number of subjects: 107
Study 20337206 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (5 mg daily)
Number of subjects: 107
Study 20337206 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (100 mg daily)
Number of subjects: 107
Study 18765955 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 2448
Study 18765955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2448
Study 15671186 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression care management intervention over 24 months
Number of subjects: 200
Study 15671186 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study 11792152 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (600 mg/day)
Number of subjects: 60
Study 11792152 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg/day)
Number of subjects: 60
Study 11792152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 11792152 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Number of subjects: 60
Study 11792152 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 60
Study 11792152 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 10414474 — intervention group
Group type: EXPERIMENTAL
Intervention: Education/behavior modification classes for 6 months
Number of subjects: 38
Study 10414474 — intervention group
Group type: COMPARATOR
Intervention: Usual office visits (Control)
Number of subjects: 38
Study 7730962 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer dentifrice (0.3% triclosan and 2.0% copolymer)
Number of subjects: 124
Study 7730962 — intervention group
Group type: COMPARATOR
Intervention: Customary oral hygiene care
Number of subjects: 124
Study 2341773 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium grommets
Number of subjects: 31
Study 2341773 — intervention group
Group type: COMPARATOR
Intervention: Shepard design Teflon grommet
Number of subjects: 31
Study 6313820 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 55
Study 6313820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 30920129 — intervention group
Group type: EXPERIMENTAL
Intervention: Good social support from family and friends
Number of subjects: 1294
Study 30920129 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 70–79 years
Number of subjects: 1294
Study 30920129 — intervention group
Group type: EXPERIMENTAL
Intervention: Age >80 years
Number of subjects: 1294
Study 30920129 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 1294
Study 30920129 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Malay
Number of subjects: 1294
Study 30920129 — intervention group
Group type: EXPERIMENTAL
Intervention: Received only informal education
Number of subjects: 1294
Study 30920129 — intervention group
Group type: EXPERIMENTAL
Intervention: Had gastritis
Number of subjects: 1294
Study 30920129 — intervention group
Group type: EXPERIMENTAL
Intervention: Had a stroke
Number of subjects: 1294
Study 30920129 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived current health status as satisfactory
Number of subjects: 1294
Study 30920129 — intervention group
Group type: EXPERIMENTAL
Intervention: Disabled based on WHO Disability Assessment Schedule
Number of subjects: 1294
Study 28889155 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US)‐guided transversus abdominis plane (TAP) block, 0.3 ml/kg of 0.25% levobupivacaine with 1/200,000 adrenalin
Number of subjects: 90
Study 28889155 — intervention group
Group type: COMPARATOR
Intervention: Ilio‐inguinal/ilio‐hypogastric (II/IH) block, 0.7 ml/kg of 0.25% levobupivacaine with 1/200,000 adrenalin
Number of subjects: 90
Study 28889155 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal block, 0.5 ml/kg of 0.25% levobupivacaine with 1/200,000 adrenalin
Number of subjects: 90
Study 26086986 — intervention group
Group type: EXPERIMENTAL
Intervention: Iyengar yoga
Number of subjects: 35
Study 26086986 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking program
Number of subjects: 35
Study 24402390 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual dietary counseling as part of a Comprehensive Geriatric Assessment
Number of subjects: 173
Study 21594236 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect composite (Estenia) with Variolink cement on non-aged composites
Number of subjects: 160
Study 21594236 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressed glass ceramic (IPS Empress II) with Variolink cement on non-aged composites
Number of subjects: 160
Study 21594236 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect composite (Estenia) with Panavia F2.0 cement on aged composites
Number of subjects: 160
Study 21594236 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressed glass ceramic (IPS Empress II) with Panavia F2.0 cement on aged composites
Number of subjects: 160
Study 21594236 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect composite (Estenia) with Variolink cement on aged composites
Number of subjects: 160
Study 21594236 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressed glass ceramic (IPS Empress II) with Variolink cement on aged composites
Number of subjects: 160
Study 21594236 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison of indirect composite and pressed glass ceramic
Number of subjects: 160
Study 21594236 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure types in indirect resin composite substrate
Number of subjects: 160
Study 21594236 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure types in ceramic substrate
Number of subjects: 160
Study 19667022 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA) alone
Number of subjects: 0
Study 19667022 — intervention group
Group type: COMPARATOR
Intervention: Mitoxantrone induction therapy followed by glatiramer acetate (GA)
Number of subjects: 0
Study 22093991 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone (2 × 15 mg for 1st postoperative 24 h; 2 × 10 mg for 2nd postoperative 24 h), paracetamol & tramadol hydrochloride tablets (8 × 1 tablet for postoperative 48 h) orally plus pethidine injection on demand (OXY group)
Number of subjects: 60
Study 22093991 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled epidural analgesia with 0.1% ropivacaine, 0.1 µg/ml sufentanil plus injected pethidine on demand (EDA group)
Number of subjects: 60
Study 22093991 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone (OXY group)
Number of subjects: 60
Study 22093991 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled epidural analgesia (EDA group)
Number of subjects: 60
Study 22093991 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 16006443 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cholesterol
Number of subjects: 895
Study 16006443 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL cholesterol
Number of subjects: 895
Study 12042673 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR 1298CC genotype
Number of subjects: 554
Study 12042673 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined heterozygosity of MTHFR 677C>T and 1298A>C polymorphisms
Number of subjects: 554
Study 12042673 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR 1298A>C polymorphism
Number of subjects: 554
Study 12042673 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR 677C>T polymorphism
Number of subjects: 554
Study 10073777 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramp protocol
Number of subjects: 24
Study 10073777 — intervention group
Group type: COMPARATOR
Intervention: Step protocol (Bruce or modified Bruce)
Number of subjects: 24
Study 7793221 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2.0 mg.kg‐1) followed by low dose (6 mg.kg‐1.h‐1) infusion
Number of subjects: 35
Study 7793221 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2.0 mg.kg‐1) followed by high dose (12 mg.kg‐1.h‐1) infusion
Number of subjects: 35
Study 7793221 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexital (1.5 mg.kg‐1) followed by low dose (5 mg.kg‐1.h‐1) infusion
Number of subjects: 35
Study 7793221 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexital (1.5 mg.kg‐1) followed by high dose (10 mg.kg‐1.h‐1) infusion
Number of subjects: 35
Study 2286598 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg once daily for seven days
Number of subjects: 282
Study 2286598 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline 100 mg twice daily for seven days
Number of subjects: 282
Study 7291971 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose subcutaneous heparin (5000 units 8 hourly)
Number of subjects: 100
Study 7291971 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose subcutaneous heparin
Number of subjects: 100
Study 29274831 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen (1 g) preoperatively
Number of subjects: 105
Study 29274831 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 105
Study 27923244 — intervention group
Group type: EXPERIMENTAL
Intervention: Prestationary intervention
Number of subjects: 317
Study 27923244 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 317
Study 23360695 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education intervention based on Pender's Health Promotion Model
Number of subjects: 100
Study 22897518 — intervention group
Group type: EXPERIMENTAL
Intervention: Studied Swahili-Swedish word pairs four times
Number of subjects: 0
Study 22897518 — intervention group
Group type: COMPARATOR
Intervention: Studied (two times) and performed delayed JOLs (two times) alternately
Number of subjects: 0
Study 20571133 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-based culturally competent person-centered care
Number of subjects: 0
Study 18490495 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 298
Study 18490495 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 1200 mg
Number of subjects: 298
Study 18490495 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 298
Study 18490495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study 18490495 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (both doses)
Number of subjects: 298
Study 15941879 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein (HP) diet
Number of subjects: 100
Study 15941879 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate (HC) diet
Number of subjects: 100
Study 15941879 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 100
Study 12609640 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone contact
Number of subjects: 444
Study 12609640 — intervention group
Group type: COMPARATOR
Intervention: E-mail contact
Number of subjects: 444
Study 10485152 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetes patients
Number of subjects: 32
Study 10485152 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic controls
Number of subjects: 32
Study 7594019 — intervention group
Group type: EXPERIMENTAL
Intervention: American patients with prior symptoms of heart disease
Number of subjects: 1212
Study 7594019 — intervention group
Group type: COMPARATOR
Intervention: Canadian patients with prior symptoms of heart disease
Number of subjects: 1212
Study 7594019 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without prior symptoms of heart disease (both Americans and Canadians)
Number of subjects: 1212
Study 7594019 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with prior symptoms of heart disease (Americans)
Number of subjects: 1212
Study 7594019 — intervention group
Group type: COMPARATOR
Intervention: Patients with prior symptoms of heart disease (Canadians)
Number of subjects: 1212
Study 1951617 — intervention group
Group type: EXPERIMENTAL
Intervention: Most-preferred tasks under nonpurposeful conditions
Number of subjects: 20
Study 1951617 — intervention group
Group type: EXPERIMENTAL
Intervention: Least-preferred tasks under nonpurposeful conditions
Number of subjects: 20